Clinical Trial Update: A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) [Phase 1]

View source ↗

Summary

This document describes a Phase 1 dose-escalation trial of PT2385 in patients with advanced clear cell renal cell carcinoma (renal cell carcinoma); the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• PT2385

Snippet

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: ccRCC, RCC | Phase 1 | Status: ACTIVE_NOT_RECRUITING